Haemonetics Corp stock (US4041191090): segment restructuring shifts focus to Apheresis and MedSurg

Haemonetics Corp has announced a major change to its financial reporting structure, moving from three to two operating segments starting with the first quarter of fiscal 2027, while shares continue to trade on the NYSE in the United States.

Haemonetics Corp is in focus after the Boston-based medical technology group announced a comprehensive restructuring of its financial reporting segments, a change that will align its external disclosure more closely with how management runs the business and allocates capital. According to a company press release distributed via PR Newswire on 06/05/2026, Haemonetics will move from three reportable segments to two, combining the former Plasma and Blood Center units into a new Apheresis segment and renaming the Hospital segment as MedSurg, with the new structure taking effect in the first quarter of fiscal year 2027, which commenced on 03/29/2026, as stated by Haemonetics and PR Newswire on 06/05/2026.

The company’s shares remain listed in the United States on the New York Stock Exchange under the ticker HAE, with the stock representing exposure to the US medical-technology sector and to demand for blood and plasma collection systems. As of 06/05/2026, Haemonetics shares traded around the mid-USD 80 range on the NYSE, according to price information summarized by Invezz and other market-data providers referencing exchange quotes as of 06/05/2026. This positions the stock firmly within the US mid-cap healthcare technology universe while the group prepares investors for a new way of looking at its financial performance from fiscal 2027 onward.

Beyond the US home market, Haemonetics is also accessible to German investors via secondary trading venues such as Tradegate and Frankfurt, where the stock is quoted in euros, providing a bridge for European retail investors who follow US-listed healthcare names. The core regulatory and reporting anchor, however, remains in the United States, where Haemonetics files its financial statements and segment disclosures with the Securities and Exchange Commission and communicates major changes such as the reporting reorganization through US-based investor-relations channels and recognized newswires.

The reporting change was formally detailed in a communication carried on PR Newswire on 06/05/2026, in which Haemonetics explained that the Apheresis segment will encompass its technologies used in plasma collection and blood center operations, while MedSurg will reflect products and services oriented toward hospital settings, according to Haemonetics and PR Newswire on 06/05/2026. This follows the company’s longstanding strategic emphasis on providing integrated blood-management and plasma-collection solutions to healthcare providers and blood centers globally, and the new segmentation is intended to simplify the way investors track performance across these businesses.

In the same release, Haemonetics noted that it has published a supplemental presentation recasting historical quarterly revenue for fiscal years 2024, 2025, and 2026 under the new two-segment framework, allowing investors to compare the upcoming fiscal 2027 figures against a consistent base, as detailed in the company’s statement on PR Newswire dated 06/05/2026. The company added that the presentation also includes a recast of its previously issued fiscal 2027 revenue guidance on the new segment basis, but emphasized that the document does not reaffirm or update that guidance, with any potential changes to outlook to be addressed on the first-quarter fiscal 2027 earnings call, according to Haemonetics via PR Newswire on 06/05/2026.

Haemonetics described the reorganization as a reflection of how the business is currently managed, noting that combining Plasma and Blood Center into Apheresis should help streamline reporting, improve transparency on margin and growth dynamics in that franchise, and make it easier for investors to evaluate the performance of hospital-focused activities in MedSurg separately, as reported by PR Newswire and summarized by Barchart on 06/05/2026. Third-party coverage from MarketScreener and other financial-news outlets reiterated that the company will report under the two-segment structure starting with the first quarter of fiscal 2027, which began on 03/29/2026, reinforcing the timing and scope of the change.

The segment reclassification does not itself alter the underlying operations or geographic footprint of Haemonetics, but it does reframe how revenue and profitability are presented across its key activities. For investors who follow the stock on US and European platforms, the availability of recast historical figures for fiscal 2024 through fiscal 2026 should provide a more consistent analytical basis to compare trends in Apheresis and MedSurg once the new reporting standard is in force, as highlighted in secondary commentary by Barchart and TradingView on 06/05/2026.

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Haemonetics Corp
• Sector/industry: Medical technology / healthcare equipment
• Headquarters/country: Boston, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Blood and plasma collection systems, transfusion technologies, hospital blood-management solutions
• Home exchange/listing venue: New York Stock Exchange (HAE)
• Trading currency: USD

Haemonetics Corp: core business model

Haemonetics Corp develops and supplies specialized technologies and disposable products that support the collection, processing, and transfusion of blood and plasma for hospitals, blood centers, and plasma-collection operators worldwide, with revenue largely generated by recurring sales of disposables and integrated equipment tied to procedure volumes in these settings.

Valuation metrics and multiples for Haemonetics Corp

While the company’s latest reporting-segment update is primarily an organizational and disclosure change, valuation metrics remain a key lens through which many investors assess Haemonetics relative to other US-listed medical-technology names. As of early June 2026, data compiled by Investing.com for Haemonetics, referencing its NYSE listing under the ticker HAE as of 06/05/2026, points to a mid-teens price-to-earnings ratio on a trailing basis, reflecting the market’s assessment of its earnings power in the blood and plasma technology niche.

In addition to the earnings multiple, enterprise-value-to-EBITDA metrics and revenue-based ratios derived from recent filings give investors a sense of how the market prices Haemonetics compared with peers in specialized medical devices and healthcare equipment. These valuation measures, as referenced in summary form on Investing.com as of 06/05/2026 and cross-checked against the company’s most recent annual report filed with the SEC, are likely to be influenced over time by how clearly the new Apheresis and MedSurg segments demonstrate growth, margin resilience, and cash generation once the fiscal 2027 reporting cycle begins.

Conclusion

The decision by Haemonetics Corp to consolidate its reporting into Apheresis and MedSurg from fiscal 2027 marks a notable shift in how investors will track the company’s financial performance, even though it does not immediately change the underlying operations. By issuing a detailed recast of historical revenue and guidance on the new basis, as outlined in its 06/05/2026 communication, the company is attempting to give the market the tools it needs to evaluate these segments more clearly once the new structure is live.

For valuation-focused investors, the transition arrives at a time when Haemonetics trades at mid-teens earnings multiples on its NYSE listing, based on data from Investing.com as of 06/05/2026, and the clarity of segment-level results may influence how those multiples evolve in comparison with other US medical-technology stocks. The interplay between the performance of the Apheresis franchise, the MedSurg hospital offering, and broader healthcare demand will likely be key factors in how the stock is assessed on both US and European trading venues after the first quarter of fiscal 2027 is reported.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.